My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Verve Therapeutics

< Previous 1 2 Next >
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Leadership Update
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Updates on its PCSK9 Program
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.